About: Quantitative mass spectrometry-based techniques for clinical use: Biomarker identification and quantification()

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Quantitative mass spectrometry-based techniques for clinical use: Biomarker identification and quantification() Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Quantitative mass spectrometry-based techniques for clinical use: Biomarker identification and quantification()
Creator	Dive, Caroline Whetton, Anthony Simpson, Kathryn
Source	Elsevier; Medline; PMC
abstract	The potential for development of personalised medicine through the characterisation of novel biomarkers is an exciting prospect for improved patient care. Recent advances in mass spectrometric (MS) techniques, liquid phase analyte separation and bioinformatic tools for high throughput now mean that this goal may soon become a reality. However, there are challenges to be overcome for the identification and validation of robust biomarkers. Bio-fluids such as plasma and serum are a rich source of protein, many of which may reflect disease status, and due to the ease of sampling and handling, novel blood borne biomarkers are very much sought after. MS-based methods for high throughput protein identification and quantification are now available such that the issues arising from the huge dynamic range of proteins present in plasma may be overcome, allowing deep mining of the blood proteome to reveal novel biomarker signatures for clinical use. In addition, the development of sensitive MS-based methods for biomarker validation may bypass the bottleneck created by the need for generation and usage of reliable antibodies prior to large scale screening. In this review, we discuss the MS-based methods that are available for clinical proteomic analysis and highlight the progress made and future challenges faced in this cutting edge area of research.
has issue date	2009-05-01(xsd:dateTime)
bibo:doi	10.1016/j.jchromb.2008.11.023
bibo:pmid	19058768
has license	no-cc
schema:url	https://doi.org/10.1016/j.jchromb.2008.11.023
resource representing a document's title	Quantitative mass spectrometry-based techniques for clinical use: Biomarker identification and quantification()
has PubMed Central identifier	PMC7185464
has PubMed identifier	19058768
schema:publication	J Chromatogr B Analyt Technol Biomed Life Sci
resource representing a document's body	covid:PMC7185464#body_text
is schema:about of	named entity 'mass spectrometry' named entity 'oncology' named entity 'peptides' named entity 'proteomic' named entity 'biomarkers' named entity 'dynamic range' named entity 'denatured proteins' named entity 'antibody' named entity 'improved patient care' named entity 'LC-MS/MS' named entity 'protein' named entity 'dynamic range' named entity 'reagent' named entity 'LC-MS/MS' named entity 'elution' named entity 'adversely affect' named entity 'infection' named entity 'benign prostate hyperplasia' named entity 'ion' named entity 'ion' named entity 'breast cancer' named entity 'Glu-C' named entity 'ion' named entity 'iTRAQ' named entity 'non-small cell lung cancer' named entity 'iTRAQ' named entity 'Biomarker' named entity 'trypsin' named entity 'colorectal cancer' named entity 'argon' named entity 'peptides' named entity 'pre-clinical studies' named entity 'peptides' named entity 'endometrial tissue' named entity 'elute' named entity 'biomarkers' named entity 'biomarker' named entity 'isotopomers' named entity 'SELDI' named entity 'plasma' named entity 'peptides' named entity 'antibodies' named entity '2D-PAGE' named entity 'biomarkers' named entity 'SCLC' named entity 'signal:noise' named entity 'trypsin' named entity 'protein' named entity 'SELDI' named entity 'protein' named entity 'prognosis' named entity 'biotin' named entity 'MS-based proteomics' named entity 'biomarker' named entity 'statistical analysis' named entity 'liquid phase' named entity 'positive correlation' named entity 'HCC' named entity 'synthetic peptides' named entity 'peptide' named entity 'disease-specific' named entity 'dynamic range' named entity 'mass spectrometer' named entity 'clinical proteomics' named entity 'bioinformatics' named entity 'pre-clinical development' named entity 'clinical proteomics' named entity 'MS/MS' named entity 'peptide' named entity 'plasma' named entity 'iTRAQ' named entity 'pathology' named entity 'clinical practice' named entity 'affinity tags' named entity 'MRM' named entity 'breast cancer' named entity 'small molecules' named entity 'charge ratio' named entity 'stable isotope labelling' named entity 'MRM'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software